Since NB cell response to dasatinib or imatinib is similar to KIT knockdown, we hypothesize that the compensatory response induced by these drugs may also be due to KIT inhibition, which induces a switch to alternative signaling through, e.g., EPOR and TRKA. The gene discussed is EPOR; the disease is neuroblastoma.